RxDoctor Payments Data

Jinfang Li, PA

Physician Assistant · Johnson City, NYNPI 1689219735

Payments from drug & device makers

$170in general payments, 2019–2025

Across 6 payments — averaging $28.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$70
  • Neurocrine Biosciences, Inc.$30
  • Avanir Pharmaceuticals, Inc.$24
  • Sunovion Pharmaceuticals Inc.$20
  • Otsuka America Pharmaceutical, Inc.$14
  • Lilly USA, LLC$12

What the payments were for

  • Food & beverage$170100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$170 in reported general payments places this provider in the 45th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$200,165
Medicare patients
172
Services billed
2,334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban386$106,737
JardianceEmpagliflozin163$51,304
EntrestoSacubitril/Valsartan160$45,370
NuplazidPimavanserin Tartrate14$40,440
XareltoRivaroxaban96$23,874
RexultiBrexpiprazole34$22,398
NuedextaDextromethorphan Hbr/Quinidine14$16,284
Emgality PenGalcanezumab-Gnlm12$8,920
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$7,516
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog36$6,746
LinzessLinaclotide11$6,200
FarxigaDapagliflozin Propanediol19$6,173
Divalproex Sodium110$6,145
JanuviaSitagliptin Phosphate20$5,559
Ranolazine ErRanolazine13$5,522

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$14$22,39834 claims
Avanir Pharmaceuticals, Inc.Nuedexta$24$16,28414 claims
AstraZenecaFarxiga$70$6,17319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Johnson City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →